在該經貿協議的第1.12條，約定了專利期限的延長。

該條的英文表述是這樣的：

Article 1.12: Effective Patent Term Extension

1. The Parties shall provide patent term extensions to compensate for unreasonable delays

that occur in granting the patent or during pharmaceutical product marketing approvals.

2. China shall provide that:

(a) China, at the request of the patent owner, shall extend the term of a patent to

compensate for unreasonable delays, not attributable to the applicant, that occur in

granting the patent. For purposes of this provision, an unreasonable delay shall at

least include a delay in the issuance of the patent of more than four years from the

date of filing of the application in China, or three years after a request for

examination of the application, whichever is later.

(b) With respect to patents covering a new pharmaceutical product that is approved for

marketing in China and methods of making or using a new pharmaceutical product

that is approved for marketing in China, China, at the request of the patent owner,

shall make available an adjustment of the patent term or the term of the patent

rights of a patent covering a new product, its approved method of use, or a method

of making the product to compensate the patent owner for unreasonable

curtailment of the effective patent term as a result of the marketing approval

process related to the first commercial use of that product in China. Any such

adjustment shall confer all of the exclusive rights, subject to the same limitations

and exceptions, of the patent claims of the product, its method of use, or its method

of manufacture in the originally issued patent as applicable to the approved product

and the approved method of use of the product. China may limit such adjustments

to no more than five years and may limit the resulting effective patent term to no

more than 14 years from the date of marketing approval in China.

3. The United States affirms that existing U.S. measures afford treatment equivalent to that

provided for in this Article.

對應的官方發布的中文文本是這樣的：

“第1.12條 專利有效期的延長

一、雙方應規定延長專利有效期以補償專利授權或藥品上市審批過程中的不合理延遲。

二、

（一）中國在專利權人的請求下，應延長專利的有效期，以補償在專利授權過程中并非由申請人引起的不合理延遲。就本條規定而言，不合理延遲應至少包含，自在中國提交申請之日起4年內或要求審查申請后3年內未被授予專利權，以較晚日期為準。

（二）對于在中國獲批上市的新藥產品及其制造和使用方法的專利，應專利權人的請求，中國應對新藥產品專利、其獲批使用方法或制造方法的專利有效期或專利權有效期提供調整，以補償由該產品首次在中國商用的上市審批程序給專利權人造成的專利有效期的不合理縮減。任何此種調整都應在同等的限制和例外條件下，授予原專利中適用于獲批產品及使用方法的對產品、其使用方法或制造方法的專利主張的全部專有權。中國可限制這種調整至最多不超過5年，且自在中國上市批準日起專利總有效期不超過14年。

三、美國確認，美國現行措施給予與本條款規定內容同等的待遇。”

為了履行《中美第一階段經貿協議》，2020年7月3日至8月16日，《中華人民共和國專利法修正案(草案) (二次審議稿) 》在中國人大網公布，向社會公眾征求意見。其中，第四十二條的修改體現了我國擬對《中美第一階段經貿協議》）第四節專利部分的第1.12條相關內容的落實。